Auburn Oncology Service launches melanoma drug clinical trialApril 5, 2018The Oncology Service at Auburn University's College of Veterinary Medicine is using the help of man's best friend in launching a clinical trial to test a new melanoma treatment drug. "This study is designed to test a new drug that may be useful in treating melanoma, which most commonly occurs in the mouth in dogs," said Bruce Smith, VMD, Ph.D., a professor in the Department of Pathobiology and director of the Auburn University Research Initiative in Cancer, or AURIC. "The drug, called MMX, is a peptide, which is a chain of amino acids, the basic building blocks of all proteins," Dr. Smith said. "This study seeks to measure the effect of this drug on these tumors. We are currently taking patients to participate in the clinical trial." Dog owners who are interested in enrolling their pets into this clinical trial must do so through the Oncology Service at the college's Wilford and Kate Bailey Small Animal Teaching Hospital. The treatment, as well as surgery to remove any tumor left at the end of the trial, will be provided at no cost to the owner. The trial initially is about a five-week …
SPONSORED CONTENTOne dose protects for 12 months.One ProHeart® 12 (moxidectin) injection puts compliance in your control. + Get started
